SCHEMBL12328263

SCHEMBL12328263

CCCCOc1cc(CCO[C@@H]2CCCC[C@H]2N2C(=O)C[C@@H](OC(C)=O)C2=O)ccc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.47
KCNA5 P22460 5/20 0.47
SCN5A Q14524 5/20 0.47
KCND2 Q9NZV8 5/20 0.47
KCNH2 Q12809 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.43
PDE4A P27815 3/20 0.41
PDE4D Q08499 3/20 0.41
KMT2A Q03164 3/20 0.41
MAPK1 P28482 2/20 0.41
PDE4B Q07343 2/20 0.41
PDE4C Q08493 2/20 0.41
MEN1 O00255 2/20 0.41
TNF P01375 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12327944 0.97 SLC6A4 (0.47) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL18596750 0.92 SLC6A4 (0.55) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL14405477 0.92 SLC6A4 (0.55) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL12052506 0.92 SLC6A4 (0.55) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL2437322 0.92 SLC6A4 (0.55) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL438872 0.89 SLC6A4 (0.46) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL12296001 0.88 SLC6A4 (0.51) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL12295982 0.88 SLC6A4 (0.51) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL12052524 0.88 SLC6A4 (0.47) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL12296012 0.86 SLC6A4 (0.48) SLC6A4KCNA5SCN5AKCND2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022098-B2 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2011-09-20 US disclosed
US-20100152276-A1 DEUTERATED AMINOCYCLOHEXYL ETHER COMPOUNDS AND PROCESSES FOR PREPARING SAME CARDIOME PHARMA CORP. (CA) 2010-06-17 US disclosed
US-7705036-B2 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2010-04-27 US disclosed
US-20070088075-A1 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088075-A1 Deuterated aminocyclohexyl ether compounds and processes for preparing same DDC, HDHD5, DDT SLC6A4 2668/4885KCNA5 2363/4885SCN5A 4208/4885
US-20100152276-A1 DEUTERATED AMINOCYCLOHEXYL ETHER COMPOUNDS AND PROCESSES FOR PREPARING SAME DDC, HDHD5, DDT SLC6A4 2668/4885KCNA5 2363/4885SCN5A 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.